Enveric Historical Financial Ratios
| ENVB Stock | USD 0.33 0.04 10.81% |
Enveric Biosciences is recently reporting on over 93 different financial statement accounts. To analyze all of these accounts together requires a lot of time and effort. However, using these accounts to derive some meaningful and actionable indicators such as PTB Ratio of 1.36 or Days Sales Outstanding of 107 will help investors to properly organize and evaluate Enveric Biosciences financial condition quickly.
Enveric |
About Enveric Financial Ratios Analysis
Enveric BiosciencesFinancial ratios are relationships based on a company's financial information. They can serve as useful tools to evaluate Enveric Biosciences investment potential. Financial ratio analysis can also be defined as the process of presenting financial ratios, which are mathematical indicators calculated by comparing key financial information appearing on Enveric financial statements. Financial ratios are useful tools that help investors analyze and compare relationships between different pieces of financial information across Enveric Biosciences history.
Enveric Biosciences Financial Ratios Chart
Add Fundamental
Price To Sales Ratio
Price to Sales Ratio is figured by comparing Enveric Biosciences stock price to its revenues. An advantage to using Price to Sales ratio is that it is based on Enveric Biosciences sales, a figure that is much harder to manipulate than other Enveric Biosciences multiples. Because sales tend to be more stable P/S ratio can be a good tool for screening cyclical companies fluctuating earnings patterns. A valuation ratio that compares a company's stock price to its revenues, calculated by dividing the company's market cap by its total sales or revenue over a 12-month period.Dividend Yield
Dividend Yield is Enveric Biosciences dividend as a percentage of Enveric Biosciences stock price. Enveric Biosciences dividend yield is a measure of Enveric Biosciences stock productivity, which can be interpreted as interest rate earned on an Enveric Biosciences investment. A financial ratio that shows how much a company pays out in dividends each year relative to its stock price, calculated as annual dividends per share divided by price per share.Ptb Ratio
Price-to-Book ratio, a financial valuation metric used to compare a company's current market price to its book value. It provides insight into the value that market participants place on the company's equity relative to its net asset value.Average Payables
The average amount owed to suppliers and creditors over a specific period, reflecting the company's payment cycle and credit terms with suppliers.Most ratios from Enveric Biosciences' fundamentals are interrelated and interconnected. However, analyzing fundamentals ratios one by one will only give a small insight into Enveric Biosciences current financial condition. On the other hand, looking into the entire matrix of fundamentals ratios, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Enveric Biosciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real. For information on how to trade Enveric Stock refer to our How to Trade Enveric Stock guide.At present, Enveric Biosciences' Days Sales Outstanding is projected to decrease significantly based on the last few years of reporting. The current year's Average Payables is expected to grow to about 653.5 K, whereas Price To Sales Ratio is forecasted to decline to 0.33.
| 2018 | 2023 | 2024 (projected) | Dividend Yield | 503.5K | 453.2K | 475.8K | Price To Sales Ratio | 0.0965 | 0.34 | 0.33 |
Enveric Biosciences fundamentals Correlations
Click cells to compare fundamentals
Enveric Biosciences Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Enveric Biosciences fundamentals Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Ptb Ratio | 1.12 | 7.18 | 0.98 | 0.2 | 1.43 | 1.36 | |
| Book Value Per Share | 401.8 | 29.68 | 47.22 | 10.76 | 0.91 | 0.86 | |
| Free Cash Flow Yield | (0.21) | (0.16) | (0.56) | (5.9) | (5.02) | (4.77) | |
| Operating Cash Flow Per Share | (92.8) | (33.79) | (24.26) | (11.86) | (6.53) | (6.85) | |
| Pb Ratio | 1.12 | 7.18 | 0.98 | 0.2 | 1.43 | 1.36 | |
| Free Cash Flow Per Share | (95.99) | (34.18) | (26.09) | (12.26) | (6.53) | (6.86) | |
| Roic | (0.44) | (1.53) | (2.5) | (1.72) | (8.42) | (8.0) | |
| Net Income Per Share | (211.99) | (55.5) | (103.69) | (12.77) | (0.008009) | (0.008409) | |
| Payables Turnover | 6.76 | 0.18 | 1.0 | 0.94 | 0.33 | 0.32 | |
| Cash Per Share | 16.32 | 13.72 | 36.74 | 12.26 | 1.06 | 1.01 | |
| Pocfratio | (4.87) | (6.3) | (1.92) | (0.18) | (0.2) | (0.21) | |
| Interest Coverage | (9.15) | (12.62) | (6.3K) | (5.2K) | (4.4K) | (4.2K) | |
| Pfcf Ratio | (4.71) | (6.23) | (1.78) | (0.17) | (0.2) | (0.21) | |
| Days Payables Outstanding | 53.97 | 2.1K | 365.95 | 388.55 | 1.1K | 1.2K | |
| Income Quality | 0.41 | 0.57 | 0.23 | 0.93 | 0.82 | 0.77 | |
| Roe | (0.53) | (1.87) | (2.2) | (1.26) | (0.008839) | (0.009281) | |
| Ev To Operating Cash Flow | (6.68) | (5.9) | (0.42) | 0.85 | (0.0368) | (0.0386) | |
| Pe Ratio | (2.13) | (3.84) | (0.45) | (0.16) | (162.32) | (170.44) | |
| Return On Tangible Assets | (0.73) | (2.8) | (2.69) | (0.96) | (0.004229) | (0.00444) | |
| Ev To Free Cash Flow | (6.46) | (5.83) | (0.39) | 0.83 | (0.0368) | (0.0386) | |
| Earnings Yield | (0.47) | (0.26) | (2.23) | (6.14) | (0.006161) | (0.006469) | |
| Intangibles To Total Assets | 0.69 | 0.44 | 0.32 | 0.0194 | 0.0491 | 0.0466 | |
| Net Debt To E B I T D A | (1.91) | 0.25 | 0.27 | 0.9 | 0.13 | 0.14 | |
| Current Ratio | 0.53 | 3.35 | 8.51 | 4.61 | 1.53 | 1.45 | |
| Tangible Book Value Per Share | (253.17) | 13.89 | 29.2 | 10.5 | 0.81 | 0.85 | |
| Graham Number | 1.4K | 192.53 | 331.93 | 54.0 | 0.4 | 0.38 |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Enveric Biosciences offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Enveric Biosciences' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Enveric Biosciences Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Enveric Biosciences Stock:Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Enveric Biosciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real. For information on how to trade Enveric Stock refer to our How to Trade Enveric Stock guide.You can also try the Competition Analyzer module to analyze and compare many basic indicators for a group of related or unrelated entities.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Enveric Biosciences. If investors know Enveric will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Enveric Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.42) | Revenue Per Share 37.678 | Quarterly Revenue Growth (0.07) | Return On Assets (0.81) | Return On Equity (2.06) |
The market value of Enveric Biosciences is measured differently than its book value, which is the value of Enveric that is recorded on the company's balance sheet. Investors also form their own opinion of Enveric Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Enveric Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Enveric Biosciences' market value can be influenced by many factors that don't directly affect Enveric Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Enveric Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Enveric Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Enveric Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.